Display options
Cite
Zareifopoulos N, Skaltsa M, Dimitriou A, et al. Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. Eur Rev Med Pharmacol Sci. 2021;25(13):4514-4519doi: 10.26355/eurrev_202107_26243.
Zareifopoulos, N., Skaltsa, M., Dimitriou, A., Karveli, M., Efthimiou, P., Lagadinou, M., Tsigkou, A., & Velissaris, D. (2021). Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. European review for medical and pharmacological sciences, 25(13), 4514-4519. https://doi.org/10.26355/eurrev_202107_26243
Zareifopoulos, N, et al. "Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa." European review for medical and pharmacological sciences vol. 25,13 (2021): 4514-4519. doi: https://doi.org/10.26355/eurrev_202107_26243
Zareifopoulos N, Skaltsa M, Dimitriou A, Karveli M, Efthimiou P, Lagadinou M, Tsigkou A, Velissaris D. Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa. Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4514-4519. doi: 10.26355/eurrev_202107_26243. PMID: 34286493.
Copy Download .nbib Format: NLM
Share it on

Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4514-4519. doi: 10.26355/eurrev_202107_26243.

Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa.

European review for medical and pharmacological sciences

N Zareifopoulos, M Skaltsa, A Dimitriou, M Karveli, P Efthimiou, M Lagadinou, A Tsigkou, D Velissaris

Affiliations

  1. Department of Psychiatry, General Hospital of Nikea and Pireus Hagios Panteleimon, Patras, Greece. [email protected].

PMID: 34286493 DOI: 10.26355/eurrev_202107_26243

Abstract

OBJECTIVE: Drugs affecting dopaminergic neurotransmission may exert toxic and beneficial effects that persist after discontinuation by modulating gene expression in key brain regions. Drug addiction, cravings and the tardive symptoms associated with chronic exposure to antipsychotics are among the most common processes attributed to long-term dopaminergic neurotoxicity. The purpose of this review was to investigate the mechanisms of dopaminergic neurotoxicity induced by neuroleptic drugs, dopamine agonists, levodopa, stimulants and known dopaminergic neurotoxins MATERIALS AND METHODS: A PubMed search for each of the dopaminergic compounds in question was carried out. The heterogenous nature of the relevant preclinical studies precluded a systematic review, so a narrative review was carried out.

RESULTS: The dopaminergic neurotoxins 6-oxidopamine and 1-methyl-4-phenyl-tetrahydropyridine (MPTP) promote oxidative stress and inhibit mitochondrial function, while their affinity for the dopamine transporter ensures they are attain toxic intracellular concentrations exclusively in dopaminergic neurons. Stimulants which inhibit the vesicular monoamine transporter such as amphetamine and its derivatives promote oxidative stress by greatly increasing intracellular dopamine concentrations and enabling dopamine autooxidation. Antipsychotics increase dopamine release and turnover by blocking autoinhibitory D2 receptors and lead to upregulation of post-synaptic D2 receptors. Dopamine agonists may slow the progression of Parkinson's disease by reducing dopamine turnover, but downregulation of D2 receptors may underlie their behavioural toxicity.

CONCLUSIONS: Though the mechanisms have not been completely elucidated yet, it seems drugs which affect dopaminergic neurotransmission may exert long-term effects which reverse slowly upon discontinuation, if at all. Until the nature of these changes is clear it would be best to utilize drugs which affect dopaminergic neurotransmission cautiously especially if prolonged treatment is required.

Publication Types